Charles River Laboratories Intl. Inc (NYSE:CRL) has been given a consensus recommendation of “Buy” by the eighteen brokerages that are presently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $141.38.

Several equities research analysts have recently issued reports on CRL shares. SunTrust Banks raised their price objective on Charles River Laboratories Intl. to $151.00 and gave the company a “buy” rating in a research note on Thursday, February 14th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $162.00 price objective on shares of Charles River Laboratories Intl. in a research note on Thursday, February 14th. Barclays reaffirmed a “hold” rating and issued a $135.00 price objective on shares of Charles River Laboratories Intl. in a research note on Thursday, February 14th. KeyCorp raised their price objective on Charles River Laboratories Intl. from $140.00 to $151.00 and gave the company an “overweight” rating in a research note on Monday, March 11th. Finally, ValuEngine lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Friday, January 4th.

Shares of NYSE:CRL traded up $1.64 during trading on Monday, hitting $135.14. The company had a trading volume of 699,332 shares, compared to its average volume of 393,447. The firm has a market capitalization of $6.59 billion, a price-to-earnings ratio of 22.41, a PEG ratio of 1.84 and a beta of 1.03. Charles River Laboratories Intl. has a one year low of $102.96 and a one year high of $149.07. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.61 and a quick ratio of 1.38.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 13th. The medical research company reported $1.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.10. The business had revenue of $605.53 million during the quarter, compared to analyst estimates of $589.86 million. Charles River Laboratories Intl. had a return on equity of 24.09% and a net margin of 9.99%. The company’s revenue for the quarter was up 26.5% on a year-over-year basis. During the same period last year, the company earned $1.40 EPS. As a group, analysts expect that Charles River Laboratories Intl. will post 6.48 earnings per share for the current fiscal year.

In related news, VP William D. Barbo sold 8,155 shares of the firm’s stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $141.03, for a total transaction of $1,150,099.65. Following the completion of the sale, the vice president now directly owns 31,756 shares of the company’s stock, valued at approximately $4,478,548.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David Ross Smith sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $145.43, for a total value of $581,720.00. Following the sale, the chief financial officer now directly owns 24,262 shares of the company’s stock, valued at $3,528,422.66. The disclosure for this sale can be found here. Insiders have sold a total of 32,428 shares of company stock valued at $4,597,693 over the last three months. 2.10% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of the stock. Tompkins Financial Corp increased its holdings in Charles River Laboratories Intl. by 63.1% during the 1st quarter. Tompkins Financial Corp now owns 199 shares of the medical research company’s stock worth $27,000 after purchasing an additional 77 shares during the period. Fort L.P. purchased a new position in Charles River Laboratories Intl. during the 4th quarter worth $27,000. Sageworth Trust Co purchased a new position in Charles River Laboratories Intl. during the 1st quarter worth $37,000. Riverview Trust Co purchased a new position in Charles River Laboratories Intl. during the 4th quarter worth $30,000. Finally, Financial Gravity Wealth Inc. purchased a new position in Charles River Laboratories Intl. during the 1st quarter worth $59,000. 94.10% of the stock is owned by hedge funds and other institutional investors.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

See Also: Is the QQQ ETF safe?

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.